Every material Form 8-K JOINT Corp has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
The Joint Corp. reported third quarter 2026 revenue of $13.6 million, up 1% from the prior year, and a consolidated net loss of $117,000 compared with net income of $855,000 a year earlier. Net income from continuing operations rose to $1.5 million, but the company lowered its full-year 2026 system-wide sales guidance, kept Adjusted EBITDA guidance unchanged, and its board authorized an additional $5.0 million for stock repurchases.
Q3 2026 revenue was $13.6 million, compared with $13.4 million in Q3 2025; system-wide sales fell 3.1% to $123.3 million.
Consolidated net loss was $117,000 (EPS $(0.01)), versus net income of $855,000 in Q3 2025; continuing operations net income was $1.5 million, versus $290,000.
2026 system-wide sales guidance was cut to $508 million to $512 million from $519 million to $552 million; Adjusted EBITDA guidance of $12.5 million to $13.5 million was unchanged.
On November 3, 2026, the board authorized an additional $5.0 million for stock repurchases, running until November 4, 2027; the company repurchased $3.8 million of stock in Q3 2026.
Joint Corp. agreed on October 1, 2026 to reacquire certain Texas regional development rights from franchisee sellers and terminate the related regional developer agreements, effective 12:01 a.m. that day. The company will pay $8.0 million in cash at signing, plus up to $2.0 million more tied to gross sales metrics over two annual periods starting September 1, 2026.
Cash payment of $8.0 million due upon execution of the agreement
Up to $2.0 million in additional payments, contingent on gross sales metrics for the two annual periods beginning September 1, 2026
Sellers received about $2.3 million in royalties from Texas franchisees in the twelve months ended August 31, 2026
As of October 1, 2026, the Texas region included 141 franchised clinics; sellers will keep franchising eight clinics in Texas through affiliates
The Joint Corp. reported second quarter 2026 results on August 6, 2026. Revenue rose 14% to $15.2 million and consolidated net income rose to $653,000 from $93,000, while system-wide sales fell 3.7% and consolidated Adjusted EBITDA was flat at $3.2 million. The company reiterated its 2026 guidance rather than changing it, so shareholders get improved revenue and profit with no guidance change.
Revenue was $15.2 million for the quarter ended June 30, 2026, versus $13.3 million a year earlier.
Consolidated net income was $653,000 versus $93,000; diluted EPS was $0.05 versus $0.01.
Net loss from continuing operations narrowed to $251,000 from $1.0 million; consolidated Adjusted EBITDA was $3.2 million, unchanged year over year.
The company reiterated 2026 guidance, including system-wide sales of $519 million to $552 million and Adjusted EBITDA of $12.5 million to $13.5 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every JOINT Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →